http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2922231-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9ae1a0af7059b6d1c45022d94722710 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-99 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2016-01-22^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-09-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36bbfc1bdccfa40ba39069d5cd088491 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42b2deffeee6bc67cf46524f1fa53a8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bb71b9358d061537afc0b2498071e8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3352b6da06f5645373fb7cfa35d87ebd |
| publicationDate | 2022-09-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2922231-T3 |
| titleOfInvention | universal killer T cell |
| abstract | The present invention relates to a modified natural killer (NK) cell and its use in personalized medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they can be administered to any recipient subject without being rejected by the host's immune system (they are "universal"). In a first embodiment, non-immunogenic NK cells are modified to express CD3 to allow a T cell receptor (TCR) to be expressed. In a further embodiment, non-immunogenic NK cells are further modified to express a TCR in conjunction with the CD3 co-receptor. Co-expression of CD3 with a specific TCR results in modified NK cells that show antigen-specific cytotoxicity towards target cells. Therefore, universal NK cells can target specific antigens and thus can be used in personalized medicine, particularly in the field of oncology. (Automatic translation with Google Translate, without legal value) |
| priorityDate | 2015-01-23^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 74 of 74.